Ascendis Pharma A/S - ADR (ASND)

Historical Holders from Q1 2015 to Q3 2025

Symbol
ASND on Nasdaq
Type / Class
Equity / ADR
Shares outstanding
55,574,229
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
63,798,065
Holdings value
$12,683,754,833
% of all portfolios
0.023%
Number of holders
275
Number of buys
153
Number of sells
-114
Average buys %
+0%
Average sells %
-0.01%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ascendis Pharma A/S - ADR (ASND)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WESTFIELD CAPITAL MANAGEMENT CO LP 9.18% $887,005,948 5,528,239 Westfield Capital Management Company, L.P. 31 Dec 2024
FMR LLC 8% $745,602,004 4,646,943 FMR LLC 31 Mar 2025
JANUS HENDERSON GROUP PLC 7.8% -2.5% $859,467,360 -$20,821,968 4,323,059 -2.4% JANUS HENDERSON GROUP PLC 30 Sep 2025
Capital International Investors 5.6% $548,747,120 3,109,225 Capital International Investors 30 Jun 2025
T. Rowe Price Investment Management, Inc. 4.8% -26.7% $530,338,200 -$182,106,580 2,667,563 -25.6% T. Rowe Price Investment Management, Inc. 30 Sep 2025

Institutional Holders of Ascendis Pharma A/S - ADR (ASND)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 63,798,065 $12,683,754,833 +$232,138,587 $198.81 275
2025 Q2 62,895,390 $10,855,906,781 -$373,773,069 $172.6 245
2025 Q1 65,180,066 $10,147,446,038 +$223,136,493 $155.86 241
2024 Q4 63,751,521 $8,776,308,689 +$115,863,512 $137.67 212
2024 Q3 62,595,716 $9,312,956,409 +$237,478,312 $149.31 218
2024 Q2 60,687,245 $8,276,478,215 -$25,623,552 $136.38 202
2024 Q1 60,791,422 $9,189,438,728 +$198,420,492 $151.17 188
2023 Q4 60,262,338 $7,590,188,894 -$95,295,592 $125.95 183
2023 Q3 60,279,508 $5,644,577,484 -$61,738,785 $93.64 157
2023 Q2 61,039,136 $5,447,708,812 -$42,606,636 $89.25 156
2023 Q1 60,982,797 $6,535,152,679 -$603,913,240 $107.22 160
2022 Q4 65,956,055 $8,054,269,679 -$66,421,048 $122.13 183
2022 Q3 66,716,414 $6,891,080,476 +$149,538,106 $103.26 177
2022 Q2 63,211,628 $5,875,622,934 +$99,259,708 $92.96 162
2022 Q1 61,928,932 $7,267,064,424 +$416,027,513 $117.36 169
2021 Q4 58,376,386 $7,851,336,290 -$60,447,865 $134.53 168
2021 Q3 58,008,737 $9,244,880,979 +$506,030,857 $159.39 162
2021 Q2 55,049,436 $7,239,726,130 +$277,622,452 $131.55 167
2021 Q1 52,687,197 $6,790,538,552 -$259,999,867 $128.88 172
2020 Q4 54,357,110 $9,065,494,890 +$123,538,090 $166.78 173
2020 Q3 53,548,292 $8,263,618,101 +$776,855,285 $154.32 150
2020 Q2 48,248,343 $7,132,005,530 +$39,025,561 $147.9 149
2020 Q1 47,871,754 $5,391,239,456 +$191,350,357 $112.61 143
2019 Q4 46,149,738 $6,420,287,137 -$13,680,500 $139.12 139
2019 Q3 46,122,563 $4,442,511,426 -$194,325,083 $96.32 127
2019 Q2 47,663,417 $5,487,484,115 +$237,283,765 $115.15 132
2019 Q1 45,989,019 $5,412,737,939 +$716,635,309 $117.7 137
2018 Q4 40,100,469 $2,509,199,237 -$10,826,186 $62.65 102
2018 Q3 40,188,306 $2,847,498,166 +$44,455,437 $70.86 94
2018 Q2 39,572,750 $2,632,379,192 +$96,237,781 $66.52 100
2018 Q1 38,126,373 $2,493,396,132 +$345,130,853 $65.4 89
2017 Q4 30,513,340 $1,222,363,447 +$50,139,269 $40.06 64
2017 Q3 28,774,674 $1,042,816,000 +$204,057,698 $36.25 59
2017 Q2 23,269,447 $646,000,000 +$80,276,736 $27.76 34
2017 Q1 20,898,775 $585,169,000 +$9,050,400 $28 34
2016 Q4 20,561,240 $416,160,000 +$130,784,664 $20.24 31
2016 Q3 13,995,656 $281,311,000 +$4,791,129 $20.1 22
2016 Q2 13,876,594 $184,147,000 +$10,182,326 $13.27 23
2016 Q1 12,036,579 $223,242,000 +$9,842,726 $18.55 25
2015 Q4 10,090,990 $184,865,000 +$7,675,460 $18.32 24
2015 Q3 8,925,979 $157,986,000 -$15,929 $17.7 24
2015 Q2 8,953,630 $157,820,000 +$7,731,541 $17.68 32
2015 Q1 8,477,992 $145,818,000 +$145,818,000 $17.35 35